WE@HealthTech
Anat Arbel Shamir has extensive experience in public policy, health system access, and international trade, currently serving as Public Policy Lead at Roche since March 2020. In addition to leading Roche for a Better Future and acting as Health System Public Policy Partner, Anat is involved with WE@HealthTech and the Israel-America Chamber of Commerce as a member of the leadership team for the AmCham Pharma Committee. Previous roles include VP of Access, Regulation & International Affairs at Pharma Israel and various directorial positions within the Foreign Trade Administration of Israel. Anat holds an MBA from The Hebrew University of Jerusalem and dual bachelor's degrees in Economics and International Relations from both The Hebrew University and Vrije Universiteit Brussel.
This person is not in the org chart
WE@HealthTech
Women comprise about 70% of the HealthTech industry work force. Out of the 30 companies listed in the Biomed Index there are only two women CEOs amongst a total of sixty CEOs and Chairmen. The share value of companies that include women on their boards are higher by an average of 44% (Goldman Sachs). FORTUNE 500 companies with a larger number of women in senior management positions have better financial results (Catalyst). It follows that proper representation of women in top managerial levels will serve not only social and gender equality goals, but also organizational, business, and economic goals and performance. In partnership with 8400 we introduce a HealthTech launchpad program to promote junior women managers to executive positions throughout the ecosystem.